Category: JCN Newswire

KYOTO, JAPAN, Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Valuufy, a pioneering fintech startup drawn from a decades’ work in measuring and creating sustainable value at Doshisha University’s Value Research Center, has launched with its groundbreaking ValuuCompass, a comprehensive framework set to transform sustainable business practices and sustainability investing by providing a fully transparent and actionable framework for assessing and improving sustainability performance.The current state of sustainability reporting:· Confusing and inefficient for companies· Multiple different standards and metric· Emphasis on past activities rather than future strategies· Difficult to capture real impacts on people and the environment· No reliable benchmark for investors to assess sustainability risks and opportunitiesValuuCompass addresses precisely these challenges.The ValuuCompass addresses a critical gap in the market: the lack of a holistic, transparent system for assessing a company's true stakeholder impacts and sustainability risks that arise from these. At the heart of this new product is the Value Model, which has synthesized more than 1,200 individual impact measurements from leading global ESG and sustainability frameworks into a clear goal-based model to measure stakeholder impacts and value creation. With this new assessment system, Valuufy offers businesses and investors a clear, actionable view of value creation that goes far beyond traditional sustainability and ESG metrics. "In an era where 'value washing' - the pretence of sustainable value creation - poses significant financial and reputational risks, both companies and investors need a reliable compass," said Kyle Barnes, CEO of Valuufy. "Valuufy's products and services provide these capabilities, offering a level of transparency and insight that goes beyond all other existing solutions."Dr. Philip Sugai, Director of Research at Valuufy and Director at the Value Research Center, emphasized the revolutionary approach that Valuufy is taking: "The current systems underlying sustainability and ESG are fundamentally broken, focusing on backwards-looking disclosures rather than forward-looking strategies. Valuufy was established to change this paradigm, helping businesses to shift their focus to creating real, and measurable value across their key stakeholders."Valuufy’s ongoing activities aim to bring this important mindset to business strategy creation for businesses of all sizes. "Today, we're not just launching a new tool; we're setting a new standard for sustainable business and investing," added Marco Koeder, Chief Marketing Officer. By 2030, we aim to establish the Value Model as the global benchmark for measuring and creating sustainable value."Benefits of ValuuCompass for Companies:· First universal, objective standard to measure real impact on people and the planet· Provides actionable recommendations for improvement· Enhances performance in the sustainability reporting framework· Transforms complex data into clear, strategic insightsBenefits of ValuuCompass for Investors:· Enables truly informed decisions on sustainability risks and opportunities· Offers rigorous, quantifiable metrics for portfolio assessment· Aligns perfectly with the financial sector's data-driven approach· Provides a competitive edge in sustainable investingDiscover how Valuufy is revolutionizing the future of sustainability at www.valuufy.com.About ValuufyValuufy Inc seeks to transform how the world understands and acts on sustainability. Founded in 2024, Valuufy is a registered Japanese startup in Kyoto, Japan, born of 10 years of academic value research at Doshisha University and the Value Research Center. Led by an international team with expertise in value research, sustainability strategies, innovative technologies, business development, and ESG assessments, Valuufy provides a suite of products and services to promote value-creation activities across stakeholders for businesses of all sizes - to set new standards in transparent, data-driven decision-making in the realm of sustainability and value creation. For more, visit www.valuufy.com.The Value Research Center was officially established at Doshisha University in Kyoto, Japan, in November 2021 to develop a system for measuring, monitoring, assessing, and reporting on organizations' value creation and destruction impacts on various stakeholder groups. The result is the Value Model, which forms the foundation for ValuuCompass.Contact:Press/MediaE: news@valuufy.comT: +81-90-9742-0860Marco KoederE: marco@valuufy.com T: +49-175-999-8647 Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved in the U.S., Japan, China, South Korea, Hong Kong, and Israel, and is being marketed in the U.S., Japan, and China.LEQEMBI’s approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.(1),(2) In the UAE, it is reported that 4.09% of those over 60 years old have dementia.(3) AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.(4)Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Biogen will commercialize LEQEMBI in the UAE.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(5) Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(6) About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with LEQEMBI and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P